We often hold it to be self-evident that antibodies are key to an effective immune response against a pathogen—the more (or more potent) antibodies your body makes, the better it will fight off an ...

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of ...

The efficacy of allogeneic cell therapeutics for regenerative or oncology indications can be compromised by the emergence of antibodies against those cells, as observed in clinical trials. To overcome ...

Riliprubart is being evaluated in a phase 2 trial for the prevention and treatment of antibody-mediated rejection. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

A promising antibody failed testing. This is good news for developing a broad-spectrum antidote against the world's most dangerous snake venoms. What makes a soldier switch sides? That is a really ...

The first study, by Everly and colleagues, was a retrospective single-center analysis of 52 kidney transplant recipients with biopsy-proven acute rejection diagnosed between January 1, 2003, and ...